Interferon Alfa-2a in the Treatment of Behçet Disease

Alpsoy, Erkan; Durusoy, Çiçek; Yılmaz, Ertan; Ozgurel, Yilmaz; Ermiş, Oya; Yazar, Şahin; Başaran, Erdal

doi:10.1001/archderm.138.4.467

Cited by 238 publications

(45 citation statements)

References 25 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several researchers used their own definition of disease severity 12,32,60,65,82,115,116,117 . Similarly, many studies incorporated outcomes unique to that study for definitions of relapse, response (complete/partial), and remission (complete/partial) 30,71,72,90,118,119,120,121,122,123 .…”

Section: Resultsmentioning

confidence: 99%

“…The only organ-specific outcome measure that was developed for mucocutaneous BS and validated was the oral ulcer composite index 126 . The frequency, duration, size, pain, severity, and healing time of each of the mucocutaneous lesions were used as outcomes in different combinations in several studies 57,118,120,127-135,138-140,185,243-251 . Similarly, the number, frequency, severity, duration, and pain of arthritis episodes were reported in several studies 132,133,137,139,141,142,143 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Hatemi

Merkel²,

Hamuryudan³

et al. 2014

J Rheumatol

View full text Add to dashboard Cite

Behçet syndrome (BS) is a multisystem vasculitis that is most active during young adulthood, causing serious disability and significant impairment in quality of life. Differences in the disease course, severity, and organ involvement between patients, depending on the age at presentation and sex, makes it impossible to determine a single management strategy. The diversity and variability in the outcome measures used in clinical trials in BS makes it difficult to compare the results or inform physicians about the best management strategy for individual patients. There is a large unmet need to determine or develop validated outcome measures for use in clinical trials in BS that are acceptable to researchers and regulatory agencies. We conducted a systematic review to describe the outcomes and outcome measures that have been used in clinical trials in BS. This review revealed the diversity and variability in the outcomes and outcome measures and the lack of standard definitions for most outcomes and rarity of validated outcome tools for disease assessment in BS. This systematic literature review will identify domains and candidate instruments for use in a Delphi exercise, the next step in the development of a core set of outcome measures that are properly validated and widely accepted by the collaboration of researchers from many different regions of the world and from different specialties, including rheumatology, ophthalmology, dermatology, gastroenterology, and neurology.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Hatemi

Merkel²,

Hamuryudan³

et al. 2014

J Rheumatol

View full text Add to dashboard Cite

show abstract

“…Significantly, 20 patients (40%) continue to be off treatment after a mean follow-up of 29 months, while the remaining are on a maintenance dose of interferon-α2a. Several other small studies have also shown promising results [160, 161, 162]. A recent randomized control trial, comparing interferon-α2a to colchicine plus penicillin was unfortunately retracted due to fabrication of authorship and possibly the reported data [163].…”

Section: Treatment Optionsmentioning

confidence: 99%

Uveitis: A Potentially Blinding Disease

Durrani¹,

Meads

Murray³

2004

Ophthalmologica

262

170

View full text Add to dashboard Cite

Uveitis (intraocular inflammation) is a potentially blinding group of, probably autoimmune, conditions predominantly occurring in the working age group. Although the aetiology is unknown in most cases, many patients have an associated underlying systemic disease. Central vision loss, in the form of cystoid macular oedema, is the commonest type of visual impairment. Although historical incidence and prevalence data exists, little is known about the degree of vision loss experienced, and the social and financial consequences of having temporary or permanent visual impairment in this age group. The literature is also full of uncontrolled studies and case reports of different modalities of drug therapy for uveitis. This article attempts to raise the awareness of uveitis as an important sight-threatening group of conditions by highlighting the paucity of evidence-based data on epidemiological, quality of life, socioeconomic, and therapeutic aspects.

show abstract

“…In addition, it decreased the frequency of both genital ulcers and papulopustular lesions, and reduced the severity and rate of recurrence of attacks of eye disease. All symptoms, however, returned to pretreatment level after stopping the drug [64].…”

Section: Interferonsmentioning

confidence: 82%

Update on the Therapy of Behçets Disease

Arayssi¹

2005

CMCAIAA

View full text Add to dashboard Cite

Behçet's disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The prevalence of BD is highest in the Middle East, Mediterranean region and Asia. The usual age of onset is around 30, and the male to female ratio varies with the ethnic background. The cause of BD remains unknown. It is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. The main objectives of therapy of BD are to relieve its symptoms, decrease recurrences and prevent irreversible damage. This choice, however, is limited by the paucity of high quality therapy trials. Therapy studies for this disease in general, lack high methodological quality and common outcome measures, making treatment of this disease for the most part empirical. Most randomized studies have focused on the treatment of ocular, mucocutaneous and musculoskeletal diseases, while data on the treatment of the other manifestations is based on uncontrolled data.

show abstract

Interferon Alfa-2a in the Treatment of Behçet Disease

Cited by 238 publications

References 25 publications

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Uveitis: A Potentially Blinding Disease

Update on the Therapy of Behçets Disease

Contact Info

Product

Resources

About